In 2016, the International Consortium for Personalised Medicine (ICPerMed) was established by over 30 European members in collaboration with the European Commission. IHU PRISM, the first national center for precision medicine in oncology in France, emerged from a partnership between ICPerMed and Institut Hospitalo-Universitaire. This initiative, focusing on cancer care, received a significant €30 million grant from the French government and the French National Research Agency (ANR) as part of the FRANCE 2030 plan to drive innovation in the country. The landscape of biotech trends in Europe through 2025 and beyond is shaped by these strategic collaborations and investments.
Read more from labiotech.eu
